EDESA BIOTECH, INC. Deferred Federal Income Tax Expense (Benefit)
EDESA BIOTECH, INC. (EDSA) reported Deferred Federal Income Tax Expense (Benefit) of $2.06 million for the 12-month period ending 2018-09-30, per its 10-K filed 2018-11-30.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2018-11-30
- EDESA BIOTECH, INC. deferred federal income tax expense (benefit) for fiscal 2018 was $2.06M.
- EDESA BIOTECH, INC. deferred federal income tax expense (benefit) for fiscal 2017 was -$1.45M.
- EDESA BIOTECH, INC. deferred federal income tax expense (benefit) for fiscal 2016 was -$1.27M.
- EDESA BIOTECH, INC. deferred federal income tax expense (benefit) for fiscal 2015 was -$1.03M.
| Period end | Deferred Federal Income Tax Expense (Benefit) 1 month | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|---|
| 2018-09-30 | $2.06M 10-K · filed 2018-11-30 | |
| 2017-09-30 | -$1.45M 10-K · filed 2018-11-30 | |
| 2016-09-30 | -$1.27M 10-K · filed 2017-12-01 | |
| 2015-09-30 | -$1.03M 10-K · filed 2017-12-01 | |
| 2014-09-30 | -$107.10K 10-K · filed 2016-12-14 | |
| 2014-08-31 | -$1.43M 10-K · filed 2016-12-14 | |
| 2013-08-31 | -$738.00K 10-K · filed 2015-12-14 | |
| 2012-08-31 | -$1.17M 10-K · filed 2014-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |